Ignite Creation Date:
2025-12-25 @ 3:11 AM
Ignite Modification Date:
2026-07-08 @ 2:33 PM
Study NCT ID:
NCT01355705
Status:
COMPLETED
Last Update Posted:
2018-09-18
First Post:
2011-05-16
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma
Sponsor:
Michaela Liedtke
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Multiple Myeloma | View |
Keywords: